122 related articles for article (PubMed ID: 36993676)
41. Advances in the pharmacological management of acute myeloid leukemia in adults.
Numan Y; Abaza Y; Altman JK; Platanias LC
Expert Opin Pharmacother; 2022 Sep; 23(13):1535-1543. PubMed ID: 35938317
[TBL] [Abstract][Full Text] [Related]
42. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
[TBL] [Abstract][Full Text] [Related]
43. Combined venetoclax and alvocidib in acute myeloid leukemia.
Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
[TBL] [Abstract][Full Text] [Related]
44. Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M; Vick B; Kasper MA; Able M; Polzer H; Gerlach M; Kremmer E; Hecker JS; Schmitt S; Stengl A; Waller V; Hohmann N; Festini M; Ludwig A; Rohrbacher L; Herold T; Subklewe M; Götze KS; Hackenberger CPR; Schumacher D; Helma-Smets J; Jeremias I; Leonhardt H; Spiekermann K
Blood; 2023 Mar; 141(9):1023-1035. PubMed ID: 35981498
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Vulnerabilities in
Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
[TBL] [Abstract][Full Text] [Related]
46. Combined BCL-2 and PI3K/AKT Pathway Inhibition in
Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872
[TBL] [Abstract][Full Text] [Related]
47. ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.
Qian Y; Zhang X; Mao S; Wei W; Lin X; Ling Q; Ye W; Li F; Pan J; Zhou Y; Zhao Y; Huang X; Huang J; Tong H; Sun J; Jin J
Mol Oncol; 2023 Jul; 17(7):1402-1418. PubMed ID: 36567628
[TBL] [Abstract][Full Text] [Related]
48. Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells.
Rörby E; Adolfsson J; Hultin E; Gustafsson T; Lotfi K; Cammenga J; Jönsson JI
Exp Hematol Oncol; 2021 Feb; 10(1):7. PubMed ID: 33531064
[TBL] [Abstract][Full Text] [Related]
49. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
[TBL] [Abstract][Full Text] [Related]
50. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
[TBL] [Abstract][Full Text] [Related]
51. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Weisberg E; Liu Q; Zhang X; Nelson E; Sattler M; Liu F; Nicolais M; Zhang J; Mitsiades C; Smith RW; Stone R; Galinsky I; Nonami A; Griffin JD; Gray N
PLoS One; 2013; 8(2):e56473. PubMed ID: 23437141
[TBL] [Abstract][Full Text] [Related]
52. Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.
Brown P; Smith FO
Paediatr Drugs; 2008; 10(2):85-92. PubMed ID: 18345718
[TBL] [Abstract][Full Text] [Related]
53. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia.
Ozeki K; Kiyoi H; Hirose Y; Iwai M; Ninomiya M; Kodera Y; Miyawaki S; Kuriyama K; Shimazaki C; Akiyama H; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Ueda R; Ohno R; Emi N; Naoe T
Blood; 2004 Mar; 103(5):1901-8. PubMed ID: 14604973
[TBL] [Abstract][Full Text] [Related]
54. The role of FLT3 kinase as an AML therapy target.
Beffinger M; Skwarska A
Curr Pharm Des; 2012; 18(19):2758-65. PubMed ID: 22390761
[TBL] [Abstract][Full Text] [Related]
55. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
56. New Therapeutic Strategies for Adult Acute Myeloid Leukemia.
Ishii H; Yano S
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681786
[TBL] [Abstract][Full Text] [Related]
57. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
Carter BZ; Mak PY; Tao W; Zhang Q; Ruvolo V; Kuruvilla VM; Wang X; Mak DH; Battula VL; Konopleva M; Jabbour EJ; Hughes PE; Chen X; Morrow PK; Andreeff M
Mol Cancer Ther; 2022 Jun; 21(6):879-889. PubMed ID: 35364607
[TBL] [Abstract][Full Text] [Related]
58. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
59. Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
Yuan T; Qi B; Jiang Z; Dong W; Zhong L; Bai L; Tong R; Yu J; Shi J
Eur J Med Chem; 2019 Sep; 178():468-483. PubMed ID: 31207462
[TBL] [Abstract][Full Text] [Related]
60. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
